A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0-42 months

Wadonda-Kabondo, Nellie; Sterne, Jonathan A C; Golding, Jean; Kennedy, Cameron; Archer, Corey; Dunnill, M.G.S.

doi:10.1111/j.1365-2133.2003.05605.x

Cited by 87 publications

(70 citation statements)

References 22 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have provided conflicting evidence with respect to the importance of sex in the incidence of AD in young children. No sex effect on AD was found in children younger than 3.5 years who were studied in a retrospective populationbased postal questionnaire study in the United Kingdom 31 and in children younger than 2 years who were studied in a prospective population-based case-control study in Sweden. 18 In contrast, Harris et al 32 found boys to be more affected than girls in a cohort of children recruited before birth and followed up to age 2 years.…”

Section: Commentmentioning

confidence: 94%

Development of Atopic Dermatitis During the First 3 Years of Life

Halkjær¹,

Loland²,

Buchvald³

et al. 2006

Arch Dermatol

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 94%

Development of Atopic Dermatitis During the First 3 Years of Life

Halkjær¹,

Loland²,

Buchvald³

et al. 2006

Arch Dermatol

View full text Add to dashboard Cite

“…The incidence of allergic disorders has dramatically increased over the past decades such that these disorders are the most common chronic diseases of childhood in the developed world nowadays [1, 2]. This rise in the incidence of allergies has been linked with epidemiological evidence of a reduced microbial burden, the ‘hygiene hypothesis’ and new insights thereof [3,4,5,6].…”

Section: Introductionmentioning

confidence: 99%

Oral Treatment with Probiotics Reduces Allergic Symptoms in Ovalbumin-Sensitized Mice: A Bacterial Strain Comparative Study

Hougee

Vriesema

Wijering³

et al. 2009

Int Arch Allergy Immunol

147

View full text Add to dashboard Cite

Background/Aim: Evidence demonstrating an important role of the intestinal microbiota in the incidence of allergic disorders has led to the concept of using probiotics as possible antiallergic therapy. This study aimed to select a bacterial strain with the best antiallergic treatment effects from a panel of 6 bacterial strains in a mouse model of ovalbumin(OVA)-allergic asthma. Methods: OVA-sensitized BALB/c mice were orally administered the bacterial strains Bifidobacterium breve M-16V, B. infantis NumRes251, B. animalis NumRes252 and NumRes253, Lactobacillus plantarum NumRes8 and L. rhamnosus NumRes6. After challenge by OVA inhalation in the lungs, the response to methacholine was measured. Pulmonary inflammation was assessed by analyzing bronchoalveolar lavage fluid for the presence of eosinophils, neutrophils, macrophages and lymphocytes and for interleukin 4, interleukin 5, interleukin 10 and interferon-γ. OVA-specific IgE, IgG1 and IgG2a were measured in serum. Next, the effect on acute allergic skin reaction was measured after treatment with B. breve M-16V and L. plantarum NumRes8. Results: Of the panel of 6 strains, B. breve M-16V and L. plantarum NumRes8 inhibited (1) the response to methacholine, (2) reduced the number of eosinophils in the bronchoalveolar lavage fluid, (3) reduced both OVA-specific IgE and (4) OVA-specific IgG1, whereas the other strains did not affect all these parameters simultaneously. B. breve M-16V but not L. plantarum NumRes8 reduced interleukin 4, interleukin 5 and interleukin 10. Furthermore, B. breve M-16V but not L. plantarum NumRes8 reduced acute allergic skin reactions to OVA. Conclusion: B. breve M-16V was identified as the most potent antiallergic strain.

show abstract

“…1 Approximately 15% to 20% of infants in Western countries suffer from this disease, and the prevalence is increasing. [1][2][3][4][5] Intractable itching and related sleep loss account for much of the suffering experienced by affected infants. 6,7 AD also affects the appetite and mood of infants.…”

mentioning

confidence: 99%

Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years

et al. 2006

View full text Add to dashboard Cite

Pimecrolimus is a calcineurin inhibitor developed for the topical treatment of atopic dermatitis. During the clinical development of 1% pimecrolimus cream, 1133 patients 3 to 23 months of age with mild to severe atopic dermatitis were treated for up to 2 years. The objective of this review is to discuss the safety and tolerability of 1% pimecrolimus cream among infants, on the basis of the combined results from all studies (4 pharmacokinetic studies and 6 clinical trials) conducted among these patients. Pimecrolimus blood concentrations measured for 35 patients were consistently low (Յ1 ng/mL in Ͼ80% of samples), irrespective of the disease severity and extent, and remained low during intermittent treatment for up to 1 year. The level of systemic exposure to pimecrolimus among infants was comparable to that observed for older pediatric patients enrolled in the same studies and treated in the same way with 1% pimecrolimus cream, which indicated that young pediatric patients are not at higher risk of significant percutaneous absorption of topically applied pimecrolimus, despite their large skin surface area/body mass ratio. The 6 clinical trials included a total of 1098 infants, who were treated for periods ranging from 4 weeks to 2 years. Most of these patients (60%) had moderate to severe disease at baseline. The most frequently reported adverse events were common childhood disorders such as nasopharyngitis, pyrexia, upper respiratory tract infections, ear infections, and bronchitis. During the double-blind (DB) studies or DB phases of studies, the incidence rates for the most frequently reported adverse events were similar for patients who received 1% pimecrolimus cream and patients who received the vehicle, except for the incidence of teething, which was higher among the pimecrolimus-treated infants (relative risk: 2.02; 95% confidence interval: 1.32-3.27). Treatment with 1% pimecrolimus cream was not associated with an increase in the overall incidence of nonskin infections, compared with the vehicle (relative risk: 1.015; 95% confidence interval: 0.88 -1.18). The incidence density (ID) rates for total bacterial, fungal, parasitic, and viral skin infections during the DB studies or DB phases of www.pediatrics.org/cgi

show abstract

A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0-42 months

Cited by 87 publications

References 22 publications

Development of Atopic Dermatitis During the First 3 Years of Life

Development of Atopic Dermatitis During the First 3 Years of Life

Oral Treatment with Probiotics Reduces Allergic Symptoms in Ovalbumin-Sensitized Mice: A Bacterial Strain Comparative Study

Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years

Contact Info

Product

Resources

About